乳腺癌芳香化酶表达与临床病理因素的关系

Associations between aromatase gene expression and clinicopath- ologic factors in breast cancer

目的研究乳腺癌组织中芳香化酶基因表达与乳腺癌临床病理因素的关系。方法（1）应用实时定量PCR检测50例乳腺癌及正常乳腺组织中芳香化酶基因表达；计算肿瘤组织（T）及正常组织（N）的比值（T／N）；（2）以所有肿瘤组织芳香化酶mRNA表达量的中位值，定义各例芳香化酶表达水平的高低。结果（1）激素受体阳性组芳香化酶基因的T／N比值高于激素受体阴性组（P=0．031）；（2）年龄大于50岁组表达高于50岁以下组（P=0．008）；（3）浸润性导管癌组低于其它类型组（P=0．000）；（4）P53阳性组与阴性组表达无差异（P=0．790）；（5）肿瘤小于2cm组与大于2cm组表达无差异（P=0．429）；（6）淋巴结阳性组与淋巴结阴性组表达无差异（P=0．142）。结论（1）乳腺癌芳香化酶基因表达与激素受体、年龄、组织学类型相关，与肿瘤大小、淋巴结状况、P53表达无关。（2）在激素受体阳性、年龄大于50岁的患者中部分为芳香化酶低表达。

Objective To investigate the relationship between the aromatase gene expression and clinicopathologic factors in breast cancer. Methods The expression level of aromatase mRNA was evaluated by quantitative real-time PCR in 50 cases of breast cancer and normal breast tissues. The ratio of tumor to normal tissue（T/N） of aromatase expression was calculated for each case. Using median of aromatase mRNA level in breast cancer as cut-off point, the cases were categorized into high expression group and low expression group. Results The T/N of aromatase mRNA expression was significantly greater in the hormone receptors positive group than that in the negative group （ P = 0. 031 ）, in the group of patients older than 50 years than that in the group younger than 50 years （P = 0. 008 ）, and in other pathologic types than that in invasive ductal carcinoma （P = 0. 000）. No relationship was found between the T/N and other clinicopathologic factors, including P53 （P =0. 790）, tumor size （P =0. 429）, and axillary lymph node involvement （P =0. 142）. Conclusions Significant correlation was found between the T/N and the status of hormone receptors, age and histopathology. However, no relationship was found between aromatase mRNA expression level and any other clinicopathologic factors, including tumor size, axillary lymph node involvement and P53. In older than 50 group and hormone receptors positive group, partial patients with low aromatase expression level were found.